CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics: Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00) Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29) Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27) Key clinical trial data with surovatamig; implications for practice (32:38) Key clinical trial data with MK-1045; implications for practice (39:02) Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36) CME information and select publications